Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis

Shurong Chang, Cynthia Chambers, Fu-Tong Liu, April W. Armstrong

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Psoriasis is a chronic inflammatory disease, evolving from a complex interplay of genetic and environmental factors. In the recent years, we have seen much progress in understanding the immunopathogenesis of psoriasis, paving the way for new therapies with biologics. Currently, the most commonly used biologics in psoriasis are TNF inhibitors etanercept, infliximab and adalimumab, and the IL-12/23 inhibitor ustekinumab. As TNF inhibitors are contraindicated in patients with multiple sclerosis, ustekinumab remained the only biologic available for these patient before the recent approval of Secukinumab, an IL-17A inhibitor. Herein we report two patients with multiple sclerosis and comorbid psoriasis successfully treated with ustekinumab without progression of their multiple sclerosis. Our cases demonstrate that ustekinumab is a reasonably safe choice in this patient population. We also briefly reviewed new therapies currently under investigation, which will undoubtedly further expand our armamentarium for the treatment of psoriasis in patients with neuromuscular diseases.

Original languageEnglish (US)
JournalDermatology Online Journal
Volume21
Issue number7
StatePublished - Jul 1 2015

Fingerprint

Psoriasis
Multiple Sclerosis
Interleukin-23
Therapeutics
Neuromuscular Diseases
Biological Therapy
Interleukin-17
Interleukin-12
Biological Products
Chronic Disease
Ustekinumab
Population

Keywords

  • IL-17
  • IL-23
  • Multiple sclerosis
  • Psoriasis
  • Ustekinumab

ASJC Scopus subject areas

  • Dermatology

Cite this

Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis. / Chang, Shurong; Chambers, Cynthia; Liu, Fu-Tong; Armstrong, April W.

In: Dermatology Online Journal, Vol. 21, No. 7, 01.07.2015.

Research output: Contribution to journalArticle

Chang, S, Chambers, C, Liu, F-T & Armstrong, AW 2015, 'Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis', Dermatology Online Journal, vol. 21, no. 7.
Chang, Shurong ; Chambers, Cynthia ; Liu, Fu-Tong ; Armstrong, April W. / Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis. In: Dermatology Online Journal. 2015 ; Vol. 21, No. 7.
@article{397d8d46bdc041aba0e6c7289907ebe5,
title = "Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis",
abstract = "Psoriasis is a chronic inflammatory disease, evolving from a complex interplay of genetic and environmental factors. In the recent years, we have seen much progress in understanding the immunopathogenesis of psoriasis, paving the way for new therapies with biologics. Currently, the most commonly used biologics in psoriasis are TNF inhibitors etanercept, infliximab and adalimumab, and the IL-12/23 inhibitor ustekinumab. As TNF inhibitors are contraindicated in patients with multiple sclerosis, ustekinumab remained the only biologic available for these patient before the recent approval of Secukinumab, an IL-17A inhibitor. Herein we report two patients with multiple sclerosis and comorbid psoriasis successfully treated with ustekinumab without progression of their multiple sclerosis. Our cases demonstrate that ustekinumab is a reasonably safe choice in this patient population. We also briefly reviewed new therapies currently under investigation, which will undoubtedly further expand our armamentarium for the treatment of psoriasis in patients with neuromuscular diseases.",
keywords = "IL-17, IL-23, Multiple sclerosis, Psoriasis, Ustekinumab",
author = "Shurong Chang and Cynthia Chambers and Fu-Tong Liu and Armstrong, {April W.}",
year = "2015",
month = "7",
day = "1",
language = "English (US)",
volume = "21",
journal = "Dermatology Online Journal",
issn = "1087-2108",
publisher = "Department of Dermatology UC Davis",
number = "7",

}

TY - JOUR

T1 - Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis

AU - Chang, Shurong

AU - Chambers, Cynthia

AU - Liu, Fu-Tong

AU - Armstrong, April W.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Psoriasis is a chronic inflammatory disease, evolving from a complex interplay of genetic and environmental factors. In the recent years, we have seen much progress in understanding the immunopathogenesis of psoriasis, paving the way for new therapies with biologics. Currently, the most commonly used biologics in psoriasis are TNF inhibitors etanercept, infliximab and adalimumab, and the IL-12/23 inhibitor ustekinumab. As TNF inhibitors are contraindicated in patients with multiple sclerosis, ustekinumab remained the only biologic available for these patient before the recent approval of Secukinumab, an IL-17A inhibitor. Herein we report two patients with multiple sclerosis and comorbid psoriasis successfully treated with ustekinumab without progression of their multiple sclerosis. Our cases demonstrate that ustekinumab is a reasonably safe choice in this patient population. We also briefly reviewed new therapies currently under investigation, which will undoubtedly further expand our armamentarium for the treatment of psoriasis in patients with neuromuscular diseases.

AB - Psoriasis is a chronic inflammatory disease, evolving from a complex interplay of genetic and environmental factors. In the recent years, we have seen much progress in understanding the immunopathogenesis of psoriasis, paving the way for new therapies with biologics. Currently, the most commonly used biologics in psoriasis are TNF inhibitors etanercept, infliximab and adalimumab, and the IL-12/23 inhibitor ustekinumab. As TNF inhibitors are contraindicated in patients with multiple sclerosis, ustekinumab remained the only biologic available for these patient before the recent approval of Secukinumab, an IL-17A inhibitor. Herein we report two patients with multiple sclerosis and comorbid psoriasis successfully treated with ustekinumab without progression of their multiple sclerosis. Our cases demonstrate that ustekinumab is a reasonably safe choice in this patient population. We also briefly reviewed new therapies currently under investigation, which will undoubtedly further expand our armamentarium for the treatment of psoriasis in patients with neuromuscular diseases.

KW - IL-17

KW - IL-23

KW - Multiple sclerosis

KW - Psoriasis

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=84937156199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937156199&partnerID=8YFLogxK

M3 - Article

C2 - 26436967

AN - SCOPUS:84937156199

VL - 21

JO - Dermatology Online Journal

JF - Dermatology Online Journal

SN - 1087-2108

IS - 7

ER -